Cargando…

ERα36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway

BACKGROUND: Acquired tamoxifen resistance is one of the major barriers to the successful treatment of breast cancer. Recently, overexpression of ERα36 was demonstrated to be a potential mechanism for the generation of acquired tamoxifen resistance. This study aims to evaluate the possibility of ERα3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Guangliang, Zhang, Jing, Xu, Zhenzhen, Li, Zhongqi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969677/ https://www.ncbi.nlm.nih.gov/pubmed/32021441 http://dx.doi.org/10.2147/CMAR.S226410

Ejemplares similares

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway
por: Zhu, Linlin, et al.
Publicado: (2018)

ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways
por: Lin, Sheng-Li, et al.
Publicado: (2010)

ER-α36: a novel biomarker and potential therapeutic target in breast cancer
por: Su, Xingyun, et al.
Publicado: (2014)

Enhancement of Sensitivity to Tamoxifen by Berberine in Breast Cancer Cells by Inhibiting ER-α36 Expression
por: Pan, Xiaohua, et al.
Publicado: (2022)

Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36
por: Shen, Yingying, et al.
Publicado: (2018)

Estrogen receptor variant ER‐α36 promotes tamoxifen agonist activity in glioblastoma cells
por: Qu, Chao, et al.
Publicado: (2019)

The cyclin-like protein, SPY1, regulates the ERα and ERK1/2 pathways promoting tamoxifen resistance
por: Ferraiuolo, Rosa-Maria, et al.
Publicado: (2017)

Effects of 17β-estradiol and tamoxifen on gastric cancer cell proliferation and apoptosis and ER-α36 expression
por: Wang, Xuming, et al.
Publicado: (2017)

Estrogen Receptor (ER)-α36 Is Involved in Estrogen- and Tamoxifen-Induced Neuroprotective Effects in Ischemic Stroke Models
por: Zou, Wei, et al.
Publicado: (2015)

ER-α36, a Novel Variant of ER-α, Mediates Estrogen-Stimulated Proliferation of Endometrial Carcinoma Cells via the PKCδ/ERK Pathway
por: Tong, Jing-Shan, et al.
Publicado: (2010)

A Positive Feedback Loop of ER-α36/EGFR Promotes Malignant Growth of ER-negative Breast Cancer Cells
por: Zhang, XianTian, et al.
Publicado: (2010)

Tamoxifen enhances stemness and promotes metastasis of ERα36(+) breast cancer by upregulating ALDH1A1 in cancer cells
por: Wang, Qiang, et al.
Publicado: (2018)

Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer
por: Zheng, XQ, et al.
Publicado: (2013)

Cyanidin-3-o-glucoside directly binds to ERα36 and inhibits EGFR-positive triple-negative breast cancer
por: Wang, Li, et al.
Publicado: (2016)

ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization
por: Wrobel, Kinga, et al.
Publicado: (2016)

In vitro studies on inhibition capability of fungal-sourced bassiatin versus tamoxifen against ERα, EGFR and VEGFR on breast cancer cells
por: Özgör, Erkay, et al.
Publicado: (2021)

TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer
por: Kim, Hyunhee, et al.
Publicado: (2021)

Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer
por: Gu, Yu, et al.
Publicado: (2016)

Huaier polysaccharide inhibits the stem-like characteristics of ERα-36(high) triple negative breast cancer cells via inactivation of the ERα-36 signaling pathway
por: Hu, Baoquan, et al.
Publicado: (2019)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer
por: Kim, Yu Cheon, et al.
Publicado: (2021)

CD36 plays a critical role in proliferation, migration and tamoxifen-inhibited growth of ER-positive breast cancer cells
por: Liang, Yu, et al.
Publicado: (2018)

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα (+) breast cancer
por: Poulard, Coralie, et al.
Publicado: (2023)

Genome-wide analysis of therapeutic response uncovers molecular pathways governing tamoxifen resistance in ER+ breast cancer
por: Rahem, Sarra M., et al.
Publicado: (2020)

The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer
por: Liu, Shu-Shu, et al.
Publicado: (2020)

δEF1 Down-Regulates ER-α Expression and Confers Tamoxifen Resistance in Breast Cancer
por: Guo, Shaocong, et al.
Publicado: (2012)

ERα-36 regulates progesterone receptor activity in breast cancer
por: Konan, Henri-Philippe, et al.
Publicado: (2020)

Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo
por: Pather, K., et al.
Publicado: (2020)

Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression
por: Li, Yuanyuan, et al.
Publicado: (2017)

Identification of Tamoxifen-Resistant Breast Cancer Cell Lines and Drug Response Signature
por: Guan, Qingzhou, et al.
Publicado: (2020)

Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer
por: Perez White, Bethany, et al.
Publicado: (2013)

circRNA-SFMBT2 orchestrates ERα activation to drive tamoxifen resistance in breast cancer cells
por: Li, Zheng, et al.
Publicado: (2023)

Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells
por: Traboulsi, Tatiana, et al.
Publicado: (2018)

Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer
por: Maselli, Angela, et al.
Publicado: (2019)

miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα
por: Ouyang, Yan Xiu, et al.
Publicado: (2021)

Deciphering of a Putative GPER Recognition Domain in ERα and ERα36
por: Acramel, Alexandre, et al.
Publicado: (2022)

Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
por: Mishra, Ameet K., et al.
Publicado: (2016)

The molecular mechanisms underlying the ERα-36-mediated signaling in breast cancer
por: Omarjee, S, et al.
Publicado: (2017)

Dual Epigenetic Regulation of ERα36 Expression in Breast Cancer Cells
por: Thiebaut, Charlène, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_de079u805i1ki7fueno105i0tj